期刊文献+

重组人脑利钠肽改善慢性心力衰竭利尿剂抵抗的作用观察 被引量:3

Effects of Recombinant Human Brain Natriuretic Peptide on Improving Diuretic Resistance in Chronic Heart Failure
下载PDF
导出
摘要 目的:研究重组人脑利钠肽运用于慢性心力衰竭利尿剂抵抗的价值。方法:选择本院2018年12月~2020年6月纳入的156例慢性心力衰竭利尿剂抵抗患者为研究对象,依照随机双盲法分成重组人脑利钠肽组(A组)和常规治疗组(B组),每组78例。对两组总有效率进行评估,同时在用药前后测定两组的左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、心率(HR)、尿素氮(BUN)、肌酐(SCr)、胱抑素C(Cys-C)、脑钠肽(NT-proBNP)、白介素-2(IL-2)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平,对比两组用药结果。结果:A组总有效率(88.46%)高于B组(74.36%,P<0.05)。用药前两组的各项指标对比无统计学差异(P>0.05),用药后A组的LVEF、LVEDD、LVESD、HR、BUN、SCr、Cys-C、NT-proBNP、IL-2、IL-6、TNF-α均优于B组(P<0.05)。用药1周后A组速尿量、尿量高于B组(P<0.05)。结论:重组人脑利钠肽运用于慢性心力衰竭利尿剂抵抗的效果良好,能够有效减轻利尿剂抵抗,促进患者心功能改善,减轻炎症反应,同时快速稳定病情,为预后提供保障。 Objective:To study the value of recombinant human brain natriuretic peptide on improving diuretic resistance in chronic heart failure.Methods:A total of 156 chronic heart failure patients with diuretic resistance treated from December 2018 to June 2020 in our hospital were selected.According to random double-blind method,patients were divided into group A(n=78,recombinant human brain natriuretic peptide)and group B(n=78,routine treatment).The total effective rate of both groups was assessed.Left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),heart rate(HR),blood urea nitrogen(BUN),serum creatinine(SCr),cystatin C(Cys-C),N-terminal pro-B-type natriuretic peptide(NT-proBNP),interleukin-2(IL-2),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)of two groups were measured before and after medication.The results of medication were compared between the two groups.Results:Total effective treatment rate in group A(88.46%)was higher than group B(74.36%,P<0.05);before medication,clinical indicators between two groups showed no statistically significant difference(P>0.05);after medication,LVEF,LVEDD,LVESD,HR,BUN,SCr,Cys-C,NT-proBNP,IL-2,IL-6 and TNF-αlevels in group A were significantly better than those in group B(P<0.05).After one week of medication,the furosemidum usage volume and urine volume in group A were larger than that in group B(P<0.05).Conclusion:The effect of recombinant human brain natriuretic peptide on diuretic resistance in chronic heart failure is more prominent.It can effectively reduce the diuretic resistance and inflammatory response,stabilize the illness state,and improve the cardiac function and treatment prognosis.
作者 程雅盟 张越洋 吴静 CHENG Ya-meng;ZHANG Yue-yang;WU Jing(Department of Pharmacy,Henan Rongjun Hospital,Xinxiang 453000,China)
出处 《中国合理用药探索》 2021年第9期63-66,共4页 Chinese Journal of Rational Drug Use
关键词 利尿剂 重组人脑利钠肽 慢性心力衰竭 抵抗 心功能 diuretic recombinant human brain natriuretic peptide chronic heart failure resistance cardiac function
  • 相关文献

参考文献16

二级参考文献159

  • 1中国医师协会心力衰竭专业委员会,中华心力衰竭和心肌病杂志编辑委员会,张宇辉,许顶立,白玲.心力衰竭容量管理中国专家建议[J].中华心力衰竭和心肌病杂志(中英文),2018,2(1):8-16. 被引量:143
  • 2王方正,张澍,黄德嘉,华伟,孙宝贵,沈法荣,吴书林,王建安,方全,吴立群,王景峰,王冬梅,郭涛,陈新,中华医学会心电生理和起搏分会心脏再同步治疗专家工作组.心脏再同步治疗慢性心力衰竭的建议[J].中华心律失常学杂志,2006,10(2):90-102. 被引量:90
  • 3魏庆民,傅向华,范卫泽,谷新顺,李世强,姜云发,段江波.静脉应用重组人脑利钠肽对急性心肌梗死经皮冠状动脉介入治疗后患者心室重塑和左心功能的影响[J].中国全科医学,2007,10(8):615-617. 被引量:23
  • 4吴学明,左志通,陈艳红.血浆脑利钠肽浓度与心室重构的关系[J].中国微循环,2007,11(3):195-197. 被引量:8
  • 5Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol, 1997, 80(11A) : 15L-25L
  • 6Braunwald E,Bristow MR Congestive heart failure: fifty years of progress. Circulation, 2000, 102(20 Suppl 4) : Ⅳ14-23.
  • 7Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005, 112 (12) :e154-235.
  • 8Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary ( update 2005 ):The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26(11): 1115-1140.
  • 9Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006 : diagnosis and management. Can J Cardiol, 2006, 22 (1): 23-45.
  • 10Heart Failure Society of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail, 2006, 12 ( 1 ) : e1-2.

共引文献3977

同被引文献74

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部